Pipeline Report: May 2021
May 30th 2021
The safety and efficacy of the combination of vidutolimod and nivolumab is currently under investigation in patients with PD-1–refractory advanced melanoma.
May 27th 2021
Daiichi Sankyo Inc. is collaborating with Guardant Health Inc. to develop a companion diagnostic for fam-trastuzumab deruxtecan-nxki, which is being studied to treat patients with advanced metastatic HER2-mutated non‒small cell lung cancer.